[go: up one dir, main page]

MX2008010824A - Uso de deferiprona y metodos para tratar y/o prevenir ataxia de friedreich que resulta de manejo intracelular inadecuado de hierro. - Google Patents

Uso de deferiprona y metodos para tratar y/o prevenir ataxia de friedreich que resulta de manejo intracelular inadecuado de hierro.

Info

Publication number
MX2008010824A
MX2008010824A MX2008010824A MX2008010824A MX2008010824A MX 2008010824 A MX2008010824 A MX 2008010824A MX 2008010824 A MX2008010824 A MX 2008010824A MX 2008010824 A MX2008010824 A MX 2008010824A MX 2008010824 A MX2008010824 A MX 2008010824A
Authority
MX
Mexico
Prior art keywords
iron
deferiprone
treat
methods
friedreich ataxia
Prior art date
Application number
MX2008010824A
Other languages
English (en)
Inventor
Michael Spino
Arnold Munnich
Ioav Cabantchik
Original Assignee
Arnold Munnich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arnold Munnich filed Critical Arnold Munnich
Publication of MX2008010824A publication Critical patent/MX2008010824A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una cantidad terapéuticamente efectiva de deferiprona o deferasirox o sales fisiológicamente aceptables de los mismos para la prevención, estabilización, tratamiento, o reversión de enfermedad de FRDA inducida por hierro en pacientes que resulta de daño inducido por hierro mitocóndrico para reducir en forma preferente los depósitos de hierro en la mitocondria. Además para el tratamiento de otras condiciones que afectan el cerebro en donde un elemento clave en la generación de la patología resultante es el manejo intracelular inadecuado de hierro.
MX2008010824A 2006-02-22 2007-02-21 Uso de deferiprona y metodos para tratar y/o prevenir ataxia de friedreich que resulta de manejo intracelular inadecuado de hierro. MX2008010824A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77532006P 2006-02-22 2006-02-22
PCT/CA2007/000252 WO2007095728A1 (en) 2006-02-22 2007-02-21 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Publications (1)

Publication Number Publication Date
MX2008010824A true MX2008010824A (es) 2009-06-08

Family

ID=38436879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008010824A MX2008010824A (es) 2006-02-22 2007-02-21 Uso de deferiprona y metodos para tratar y/o prevenir ataxia de friedreich que resulta de manejo intracelular inadecuado de hierro.

Country Status (24)

Country Link
US (3) US20090023784A1 (es)
EP (1) EP1991225B1 (es)
JP (1) JP5730466B2 (es)
KR (1) KR20080104329A (es)
CN (1) CN101420954A (es)
AU (1) AU2007219009B2 (es)
BR (1) BRPI0708211A2 (es)
CA (1) CA2642778A1 (es)
DK (1) DK1991225T3 (es)
ES (1) ES2441065T3 (es)
IL (1) IL193598A (es)
MA (1) MA30266B1 (es)
MX (1) MX2008010824A (es)
MY (1) MY151412A (es)
NZ (1) NZ570730A (es)
PL (1) PL1991225T3 (es)
PT (1) PT1991225E (es)
RS (1) RS53225B (es)
RU (1) RU2008137604A (es)
SG (1) SG170020A1 (es)
SI (1) SI1991225T1 (es)
TN (1) TNSN08338A1 (es)
UA (1) UA95099C2 (es)
WO (1) WO2007095728A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095728A1 (en) * 2006-02-22 2007-08-30 Arnold Munnich The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
CN102964296B (zh) 2007-03-28 2015-03-25 阿普泰克斯科技公司 去铁酮的氟化衍生物
CN102014904B (zh) 2008-04-25 2013-02-06 阿普泰克斯科技公司 具有适口味道的去铁酮液体配制品
US20130023569A1 (en) * 2009-01-26 2013-01-24 The Trustees Of The University Of Pennsylvania Use of Deferiprone for Treatment and Prevention of Iron-Related Eye Disorders
WO2011000104A1 (en) 2009-07-03 2011-01-06 Apotex Technologies Inc. Fluorinated derivatives of 3-hydroxypyridin-4-ones
JP2012533601A (ja) 2009-07-23 2012-12-27 ノバルティス アーゲー 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
ES2466765T3 (es) 2010-08-30 2014-06-11 Roberto Testi Composiciones y métodos para el tratamiento de la Ataxia de Friedreich con interferón gamma
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
WO2013139931A1 (en) * 2012-03-21 2013-09-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Composition for use in the treatment of neurodegenerative diseases with parkinsonian syndromes
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
LT3684344T (lt) 2017-10-25 2025-09-10 Chiesi Farmaceutici S.P.A. Uždelsto atpalaidavimo deferiprono tabletės ir jų panaudojimo būdai
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
WO2025006917A1 (en) * 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Uses of iron chelators for treating stuttering

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) * 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
US20040101521A1 (en) * 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
CA2505476C (en) * 2002-11-07 2015-05-26 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
WO2007095728A1 (en) * 2006-02-22 2007-08-30 Arnold Munnich The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Also Published As

Publication number Publication date
PL1991225T3 (pl) 2014-04-30
DK1991225T3 (da) 2013-12-16
AU2007219009B2 (en) 2012-12-20
NZ570730A (en) 2013-05-31
CN101420954A (zh) 2009-04-29
ES2441065T3 (es) 2014-01-31
MY151412A (en) 2014-05-30
BRPI0708211A2 (pt) 2011-05-17
IL193598A (en) 2012-08-30
JP2009527506A (ja) 2009-07-30
AU2007219009A1 (en) 2007-08-30
MA30266B1 (fr) 2009-03-02
KR20080104329A (ko) 2008-12-02
US20070197649A1 (en) 2007-08-23
TNSN08338A1 (en) 2009-12-29
IL193598A0 (en) 2009-08-03
EP1991225B1 (en) 2013-11-06
WO2007095728A1 (en) 2007-08-30
PT1991225E (pt) 2014-02-13
SG170020A1 (en) 2011-04-29
EP1991225A4 (en) 2009-07-29
RS53225B (sr) 2014-08-29
EP1991225A1 (en) 2008-11-19
RU2008137604A (ru) 2010-03-27
UA95099C2 (ru) 2011-07-11
SI1991225T1 (sl) 2014-02-28
US20090023784A1 (en) 2009-01-22
CA2642778A1 (en) 2007-08-30
US20130190365A1 (en) 2013-07-25
JP5730466B2 (ja) 2015-06-10

Similar Documents

Publication Publication Date Title
MY151412A (en) The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
CL2009001600A1 (es) Composicion que comprende una fuente de dioxido de cloro, al menos 5 ppm de dioxido de cloro y no mas de 0,25 mg de aniones oxicloro por gramo de composiicon; util para aliviar infecciones de tejido en la cavidad oral.
MX2025004532A (es) Método para tratar el cáncer
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
CY1118033T1 (el) Φθοριωμενα παραγωγα αρυλαλκυλαμινοκαρβοξαμιδιου
PL1680112T3 (pl) N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę
NO20065662L (no) Esterlinkede makrolider nyttige for behandlingen av mikrobielle infeksjoner
WO2021038500A3 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
NZ598754A (en) Therapeutic agent for anxiety disorders
BRPI0920492A2 (pt) uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro.
PH12018502446A1 (en) (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
CN205698180U (zh) 一种肩手一体式约束带
CY1114714T1 (el) Η χρηση δεφεριπρονης και μεθοδοι για την θεραπεια και/ή προληψη της αταξιας friedreich που προκυπτει απο ενδοκυτταρικη κακη διαχειριση σιδηρου
MY158799A (en) New medical use of 3-(2,2,2-trimethylhydrazinium) propionate salts
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
WO2011044434A3 (en) A composition and a method of treating cns disorders and hyperpigmentation
EA201490173A1 (ru) Фармацевтическая композиция для лечения преждевременной эякуляции и способ лечения преждевременной эякуляции

Legal Events

Date Code Title Description
FG Grant or registration